Platelet activation by Streptococcus sanguinis is accompanied by MAP kinase phosphorylation

Platelets

Volumn 24, Issue 1, 2013, Pages 6-14

  Abdulrehman, Ahmed Y ^a   Jackson, Elke C G ^a   McNicol, Archibald ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

MAP kinases; Platelets; Signal transduction; Streptococcus sanguinis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ARGINYLGLYCYLASPARTIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; FC RECEPTOR IIA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE SYK; THROMBOXANE A2;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PREMEDICATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; STREPTOCOCCUS SANGUINIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANTIGENS, HUMAN PLATELET; ASPIRIN; BLOOD PLATELETS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGOPEPTIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; STREPTOCOCCUS SANGUIS;

STREPTOCOCCUS SANGUINIS;

EID: 84871771448     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.661105     Document Type: Article

References (53)

1. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Ann N Y Acad Sci. 2007;1108:594-602.
2. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83-92.
3. Olsen I. Update on bacteraemia related to dental procedures. Transfus Apher Sci. 2008;39:173-178.
4. Parahitiyawa NB, Jin LJ, Leung WK, Yam WC, Samaranayake LP. Microbiology of odontogenic bacteremia: Beyond endocarditis. Clin Microbiol Rev. 2009;22:46-64.
5. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol. 2006;33:401-407.
6. Persson GR, Persson RE. Cardiovascular disease and periodontitis: An update on the associations and risk. J Clin Periodontol. 2008;35:362-379.
7. de Oliveira C, Watt R, Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: Results from Scottish Health Survey. BMJ. 2010;340:c2451.
8. Iwai T. Periodontal bacteremia and various vascular diseases. J Perio Res. 2009;44:689-694.
9. Inaba H, Amano A. Roles of oral bacteria in cardiovascular diseases-from molecular mechanisms to clinical cases: Implication of periodontal diseases in development of systemic diseases. J Pharmacol Sci. 2010;113:103-109.
10. Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev. 2000;13: 547-558.
11. Teles R, Wang CY. Mechanisms involved in the association between peridontal diseases and cardiovascular disease. Oral Dis. 2011;17:450-461.
12. Ford PJ, Yamazaki K, Seymour GJ. Cardiovascular and oral disease interactions: What is the evidence? Prim Dent Care. 2007;14:59-66.
13. Kerrigan SW, Cox D. The thrombotic potential of oral pathogens. J Oral Micro. 2009;1:1-10.
14. McNicol A, Israels SJ. Mechanisms of oral bacteria-induced platelet activation. Can J Physiol Pharmacol. 2010;88: 510-524.
15. Coykendall AL. Classification and identification of the viridans streptococci. Clin Microbiol Rev. 1989;2:315-328.
16. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med. 1994;97:256-264.
17. Kaneko F, Togashi A, Saito S, Sakuma H, Oyama N, Nakamura K, Yokota K, Oguma K. Behcet's disease (Adamantiades-Behcet's disease). Clin Dev Immunol. 2011;2011:681-956.
18. Herzberg MC, Brintzenhofe KL, Clawson CC. Aggregation of human platelets and adhesion of Streptococcus sanguis. Infect Immun. 1983;39:1457-1469.
19. Douglas CW, Brown PR, Preston FE. Platelet aggregation by oral streptococci. FEMS Microbiol Lett. 1990;60:63-67.
20. Kerrigan SW, Douglas I, Wray A, Heath J, Byrne MF, Fitzgerald D, Cox D. A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. Blood. 2002;100:509-516.
21. McNicol A, Zhu R, Pesun R, Pampolina C, Jackson EC, Bowden GH, Zelinski T. A role for immunoglobulin G in donor-specific Streptococcus sanguis-induced platelet aggregation. Thromb Haemost. 2006;95:288-293.
22. Erickson PR, Herzberg MC. The Streptococcus sanguis platelet aggregation-associated protein. Identification and characterization of the minimal platelet-interactive domain. J Biol Chem. 1993;268:1646-1649.
23. Herzberg MC. Platelet-streptococcal interactions in endocarditis. Crit Rev Oral Biol Med. 1996;7:222-236.
24. Ohkuni H, Todome Y, Mizuse M, Ohtani N, Suzuki H, Igarashi H, Hashimoto Y, Ezaki T, Harada K, Imada YS, Ohkawas S, Kotani S. Biologically active extracellular products of oral viridans streptococci and the aetiology of Kawasaki disease. J Med Microbiol. 1993;39:352-362.
25. Ford I, Douglas CW, Cox D, Rees DG, Heath J, Preston FE. The role of immunoglobulin G and fibrinogen in platelet aggregation by Streptococcus sanguis. Br J Haematol. 1997;97:737-746.
26. Pampolina C, McNicol A. Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by Fc-RIIA and-IIb-3. Thromb Haemost. 2005;93:932-939.
27. McNicol A, Eyer E, Jackson EC, Israels SJ. A role for von Willebrand factor in Streptococcus sanguis-induced platelet activation. Thromb Haemost. 2007;98:1382-1384.
28. Daeron M. Structural bases of Fc-R functions. Int Rev Immunol. 1997;16:1-27.
29. Anderson GP, Anderson CL. Signal transduction by the platelet Fc receptor. Blood. 1990;76:1165-1172.
30. Fodor S, Jakus Z, Mocsai A. ITAM-based signaling beyond the adaptive immune response. Immunol Lett. 2006;104: 29-37.
31. Gratacap MP, Payrastre B, Viala C, Mauco G, Plantavid M, Chap H. Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-2 is an early key event in FcgammaRIIA-mediated activation of human platelets. J Biol Chem. 1998;273:24314-24321.
32. Ragab A, Bodin S, Viala C, Chap H, Payrastre B, Ragab-Thomas J. The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon Fc-RIIa cross-linking. J Biol Chem. 2003;278:40923-40932.
33. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol. 2006;4:445-457.
34. Kerrigan SW, Cox D. Platelet-bacterial interactions. Cell Mol Life Sci. 2010;67:513-523.
35. Adam F, Kauskot A, Rosa JP, Bryckaert M. Mitogen-activated protein kinases in hemostasis and thrombosis. J Thromb Haemost. 2008;6:2007-2016.
36. Borsch-Haubold AG, Kramer RM, Watson SP. Phosphorylation and activation of cytosolic phospholipase A2 by 38-kDa mitogen-activated protein kinase in collagenstimulated human platelets. Eur J Biochem. 1997;245: 751-759.
37. Borsch-Haubold AG, Kramer RM, Watson SP. Cytosolic phospholipase A2 is phosphorylated in collagen-and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. J Biol Chem. 1995;270:25885-25892.
38. Jackson EC, McNicol A. Cyclic nucleotides inhibit MAP kinase activity in low-dose collagen-stimulated platelets. Thromb Res. 2010;125:147-151.
39. Sullam PM, Valone FH, Mills J. Mechanisms of platelet aggregation by viridans group streptococci. Infect Immun. 1987;55:1743-1750.
40. Ford I, Douglas CW, Preston FE, Lawless A, Hampton KK. Mechanisms of platelet aggregation by Streptococcus sanguis, a causative organism in infective endocarditis. Br J Haematol. 1993;84:95-100.
41. Kramer RM, Roberts EF, Um SL, Börsch-Haubold AG, Watson SP, Fisher MJ, Jakubowski JA. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem. 1996;271: 27723-27729.
42. Börsch-Haubold AG, Ghomashchi F, Pasquet S, Goedert M, Cohen P, Gelb MH, Watson SP. Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stressactivated protein kinase pathways. Eur J Biochem. 1999; 265:195-203.
43. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc. 2000;75:369-380.
44. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood. 2009;113: 893-901.
45. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem. 2003;278: 41677-41684.
46. Robinson A, Gibbins J, Rodr?́guez-Liñ ares B, Finan PM, Wilson L, Kellie S, Findell P, Watson SP. Characterization of Grb2-binding proteins in human platelets activated by Fc-RIIA cross-linking. Blood. 1996;88:522-530.
47. Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 2008;20: 453-459.
48. McNicol A, Shibou TS, Pampolina C, Israels SJ. Incorporation of MAP kinases into the platelet cytoskeleton. Thromb Res. 2001;103:25-34.
49. Nadal F, Levy-Toledano S, Grelac F, Caen JP, Rosa JP, Bryckaert M. Negative regulation of mitogen-activated protein kinase activation by integrin-IIb-3 in platelets. J Biol Chem. 1997;272:22381-22384.
50. Saklatvala J, Rawlinson L, Waller RJ, Sarsfield S, Lee JC, Morton LF, Barnes MJ, Farndale RW. Role for p38 mitogenactivated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem. 1996;271:6586-6589.
51. Canobbio I, Reineri S, Sinigaglia F, Balduini C, Torti M. A role for p38 MAP kinase in platelet activation by von Willebrand factor. Thromb Haemost. 2004;91:102-110.
52. Kumar S, Jiang MS, Adams JL, Lee JC. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun. 1999;263:825-831.
53. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and-2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem. 1998;273:28766-28772.